Monogenic Parkinson's Disease: Genotype, Phenotype, Pathophysiology, and Genetic Testing

Genes (Basel). 2022 Mar 7;13(3):471. doi: 10.3390/genes13030471.

Abstract

Parkinson's disease may be caused by a single pathogenic variant (monogenic) in 5-10% of cases, but investigation of these disorders provides valuable pathophysiological insights. In this review, we discuss each genetic form with a focus on genotype, phenotype, pathophysiology, and the geographic and ethnic distribution. Well-established Parkinson's disease genes include autosomal dominant forms (SNCA, LRRK2, and VPS35) and autosomal recessive forms (PRKN, PINK1 and DJ1). Furthermore, mutations in the GBA gene are a key risk factor for Parkinson's disease, and there have been major developments for X-linked dystonia parkinsonism. Moreover, atypical or complex parkinsonism may be due to mutations in genes such as ATP13A2, DCTN1, DNAJC6, FBXO7, PLA2G6, and SYNJ1. Furthermore, numerous genes have recently been implicated in Parkinson's disease, such as CHCHD2, LRP10, TMEM230, UQCRC1, and VPS13C. Additionally, we discuss the role of heterozygous mutations in autosomal recessive genes, the effect of having mutations in two Parkinson's disease genes, the outcome of deep brain stimulation, and the role of genetic testing. We highlight that monogenic Parkinson's disease is influenced by ethnicity and geographical differences, reinforcing the need for global efforts to pool large numbers of patients and identify novel candidate genes.

Keywords: Parkinson’s disease; deep brain stimulation; genetic testing; genomics; monogenic.

Publication types

  • Review

MeSH terms

  • DNA-Binding Proteins / genetics
  • Genetic Testing
  • Genotype
  • Humans
  • Membrane Proteins / genetics
  • Parkinson Disease* / genetics
  • Parkinsonian Disorders* / genetics
  • Phenotype
  • Transcription Factors / genetics

Substances

  • CHCHD2 protein, human
  • DNA-Binding Proteins
  • Membrane Proteins
  • Transcription Factors